- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04507789
Exercise Therapy During Radiotherapy
February 8, 2021 updated by: Damlagül AYDIN ÖZCAN, Hacettepe University
Investigation of the Effectiveness of Exercise Training During Radiotherapy in Postoperative Breast Cancer
The main purpose of our study is to investigate the effects of exercise therapy on upper extremity functions in patients receiving radiotherapy to the axillary region after breast cancer surgery.
Study Overview
Status
Unknown
Intervention / Treatment
Detailed Description
Our study will take in place in radiation oncology clinic.
In routine the patients which will receive axillary area radiotherapy will randomized into 2 groups will explained in study arms section later.
There are papers explained about radiotherapy side effects to upper extremity functions.
But there is lack of evidence about exercise therapy during radiotherapy protocol to cope with its side effects to upper extremity functions.
In this study we will compare two groups upper extremity function related outcomes at the end of the radiotherapy sessions and also before and after results for two groups.
Study Type
Interventional
Enrollment (Anticipated)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: DAMLAGÜL AYDİN ÖZCAN
- Phone Number: +90 0312 3052525
- Email: damlagulozcan@gmail.com
Study Contact Backup
- Name: Güçlü Sezai Kılıçoğlu
- Phone Number: +90 0312 3360909
- Email: sezaikilicoglu1@gmail.com
Study Locations
-
-
Yenimahalle
-
Ankara, Yenimahalle, Turkey, 06200
- Recruiting
- Dr. Abdurrahman Yurtaslan Onkoloji Hospital
-
Contact:
- Damlagül Aydin Özcan
- Phone Number: 0530 873 99 63
- Email: damlagulozcan@gmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Patients İn the age range of 18-65
- Receiving radiotherapy to the axillary region after surgery with breast cancer diagnosis
Exclusion Criteria:
- Radiotherapy area to contain only the chest wall
- Any orthopedic injury or trauma involving the upper extremity prior to or during the cancer diagnosis
- The presence of metastases in any area other than breast tissue
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: exercise intervention group
This group will be taken an exercise intervention during their radiotherapy programme.
|
Exercise protocol will consist of the recommended special exercise sets for upper extremity problems on mastectomy patients.
The upper extremity protocol has published in 2018 by Richmond and friends called prevention of musculoskeletal shoulder problems after breast cancer treatment UK-PROSPER protocol.this
special protocol has unique exercise sets for to restore shoulder range of motion, to maintain good force level of upper extremity muscles and stretch exercises especially to the muscles around the radiotherapy area.
Exercises will be done under the supervision of a specialized physiotherapist about upper extremity disorders.
|
ACTIVE_COMPARATOR: routine radiotherapy protocol
This group will not be taken into an exercise intervention during their radiotherapy programme.
|
This intervention is only an observation to patients during their routine radiotherapy protocol.
There will be no exercise intervention for the upper extremity for the patient in this group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Upper extremity functional status of patients during radiotherapy protocol
Time Frame: ''day1 before radiotherapy session,'' ''after 6 week sessions of radiotherapy completed''
|
The subjective upper extremity functional status will assessed by The Disabilities of the Arm, Shoulder and Hand Score (DASH).
This is 30 questions Questionnaire and 21 evaluate the person's difficulties during daily activities, 5 of them (pain, stiffness, tingling, weakness) and 4 of them evaluate work, sleep, social function and self-confidence.
The person answers all questions according to the 5-point Likert system (1: no difficulty, 2: mild difficulty, 3: moderate difficulty, 4: extreme difficulty, 5: inability).
A score of 0-100 is obtained from each section.
As the score increases, the disability increases.
|
''day1 before radiotherapy session,'' ''after 6 week sessions of radiotherapy completed''
|
Shoulder joint range of motion (ROM) of patients during radiotherapy protocol
Time Frame: ''day1 before radiotherapy session,'' ''after 6 week sessions of radiotherapy completed''
|
Shoulder range of motion in flexion, abduction, internal rotation and external rotation will be evaluated by the standard goniometer.
Total Active and passive degree of ROM will be evaluated in patient sitting position.
Total ROM will record in degree value.
|
''day1 before radiotherapy session,'' ''after 6 week sessions of radiotherapy completed''
|
Hand Grip force measurement of patients during radiotherapy protocol
Time Frame: ''day1 before radiotherapy session,'' ''after 6 week sessions of radiotherapy completed''
|
Jamar hand dynamometer will be used for to evaluate gross hand grip force.
While the patient is sitting with a back support in a comfortable seat, he will be asked to grasp the dynamometer with a gross grip at 90˚ flexion and compress it as strong as she can. 3 measurements will be made for both hands and the average of the values in kg will be recorded.
|
''day1 before radiotherapy session,'' ''after 6 week sessions of radiotherapy completed''
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fear of movement, avoidance reaction of patients during radiotherapy protocol
Time Frame: ''day1 before radiotherapy session,'' ''after 6 week sessions of radiotherapy completed''
|
Tampa kinesiophobia ( fear of pain due to movement) scale will be used to evaluate the fear of movement degree.
The survey has 17 question as a scale that is answered according to the 4-point Likert system.
Total point will be between 17-68.
As the score increases, the fear of movement increases.
|
''day1 before radiotherapy session,'' ''after 6 week sessions of radiotherapy completed''
|
Physical activity level of patients during radiotherapy protocol
Time Frame: ''day1 before radiotherapy session,'' ''after 6 week sessions of radiotherapy completed''
|
It will be evaluated by a short version of the International Physical Activity survey.
The questionnaire consists of 7 questions and has open-ended questions for the physical activities to be filled in by the patient for the duration of activity and number of days.
|
''day1 before radiotherapy session,'' ''after 6 week sessions of radiotherapy completed''
|
Pain and sensory impairment of patients during radiotherapy protocol
Time Frame: ''day1 before radiotherapy session,'' ''after 6 week sessions of radiotherapy completed''
|
The McGill Pain short form scale will be used to evaluate patients sensory impairment.
In the scale, 2 scores will be counted, first one is the total number of words defined by the person related to pain and sensation.
Second score will be given by the patient to herself on visual analog scale in the range of 0-10. 10 means the worst pain while 0 is no pain.
|
''day1 before radiotherapy session,'' ''after 6 week sessions of radiotherapy completed''
|
Scapular dyskinesia of patients during radiotherapy protocol
Time Frame: ''day1 before radiotherapy session,'' ''after 6 week sessions of radiotherapy completed''
|
Lateral Slide Test method will be used to measure the scapular dyskinesia.
In this method; While the patient is in a standing position the bottom corner of the scapula will be marked and the perpendicular length to the nearest vertebra will be measured with the help of tape for both scapulae.
Then the same measurement will be repeated while the hands are at the waist and the hands are held in the 90˚ abduction position.
The difference in scapula movement for both sides will be noted in cm.
|
''day1 before radiotherapy session,'' ''after 6 week sessions of radiotherapy completed''
|
Upper extremity kinesthesia and shoulder joint position sensation of patients during radiotherapy protocol
Time Frame: ''day1 before radiotherapy session,'' ''after 6 week sessions of radiotherapy completed''
|
While the patient's eyes closed and sitting on a chair, therapist's will be brought the shoulder range of motion to 90 degrees from the 0 degree start position.
Meanwhile, angular value checks will be performed with an inclinometer fixed with velcro to mid-humeral area.
A few seconds after the position is felt, the arm will be returned to the 0 degree start position.
The patient will be asked to open his eyes and then he will be asked to actively bring his shoulder to the angle closest to the previous angle.
Measurements will be made in 3 repetitions separately for the right and left sides and the degree differences will be determined for the sense of position and the average of the results will be taken.
|
''day1 before radiotherapy session,'' ''after 6 week sessions of radiotherapy completed''
|
Lymph edema evaluation of patients during radiotherapy protocol
Time Frame: ''day1 before radiotherapy session,'' ''after 6 week sessions of radiotherapy completed''
|
The lymph edema measurement will be made with a tape.
The circumferential length around the arm will be made in every 5 cm from the distal tubercle to the shoulder.
Studies have explained that a difference of up to 2 cm between both extremities can be considered normal and moderate and excessive lymph edema classification according to the difference in measurement.
According to this staging, the severity of lymph edema in patients will be determined and recorded.
|
''day1 before radiotherapy session,'' ''after 6 week sessions of radiotherapy completed''
|
Life quality of patients during radiotherapy protocol
Time Frame: ''day1 before radiotherapy session,'' ''after 6 week sessions of radiotherapy completed''
|
It will be evaluated by EORTC QLQ-C30 (Cancer-specific quality of life index) .
the questionnaire consists of 23 questions.The person answers all the questions according to the 4-point Likert system (1: none, 2: a little, 3: quite, 4: much).
All sub scale points range between 0-100.
|
''day1 before radiotherapy session,'' ''after 6 week sessions of radiotherapy completed''
|
Breast cancer specific life quality of patients during radiotherapy protocol
Time Frame: ''day1 before radiotherapy session,'' ''after 6 week sessions of radiotherapy completed''
|
It will be evaluated by EORTC QLQ-BR23 (Breast cancer-specific quality of life index).
The questionnaire consists of 30 questions The person answers all the questions according to the 4-point Likert system (1: none, 2: a little, 3: quite, 4: much).All sub scale points range between 0-100.
|
''day1 before radiotherapy session,'' ''after 6 week sessions of radiotherapy completed''
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: YAVUZ YAKUT, Professor
- Study Chair: Güçlü Sezai Kılıçoğlu, assistant doctor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
October 10, 2020
Primary Completion (ANTICIPATED)
March 10, 2021
Study Completion (ANTICIPATED)
April 10, 2021
Study Registration Dates
First Submitted
August 4, 2020
First Submitted That Met QC Criteria
August 7, 2020
First Posted (ACTUAL)
August 11, 2020
Study Record Updates
Last Update Posted (ACTUAL)
February 10, 2021
Last Update Submitted That Met QC Criteria
February 8, 2021
Last Verified
February 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
-
Joseph Baar, MD, PhDCompletedBreast Cancer | Stage I Breast Cancer | Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
Clinical Trials on exercise intervention
-
VA Office of Research and DevelopmentRecruitingMobility Impairment | Asymptomatic Carotid Stenosis (50-69%)United States
-
The Miriam HospitalNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
University of AarhusNot yet recruiting
-
Glasgow Caledonian UniversityUnknown
-
Turku University HospitalUniversity of Turku; University of Helsinki; Academy of Finland; European Foundation... and other collaboratorsUnknownType 2 Diabetes Mellitus | Healthy VolunteersFinland
-
Sheffield Hallam UniversitySheffield Teaching Hospitals NHS Foundation TrustCompletedQuality of Life | Systemic Sclerosis | Raynaud's PhenomenonUnited Kingdom
-
VA Office of Research and DevelopmentCompletedHeart FailureUnited States
-
University Medical Center GroningenDutch Kidney Foundation; Innovation Fund of the Dutch Medical Insurance CompaniesCompletedMetabolic Syndrome | Kidney Transplant | Post-transplant Weight GainNetherlands
-
Istanbul UniversityCompletedGlenohumeral ArthritisTurkey
-
Aristotle University Of ThessalonikiCompleted